At a glance
ClinicalIndex Comparison RecordN/ACompleted
Drug / intervention
Rofecoxibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
: An End to the Yom Kippur (and Ramadan) Headache: A Double Blind Placebo Controlled Trial of Prophylactic Rofecoxib in Preventing Ritual Fasting Headache.
In Brief
A clinical study evaluating Rofecoxib for Headache. Completed, across 1 site.
Detailed Summary
Fasting is a known trigger for headache. People who fast to comply with religious edict have been shown to be prone to headache which becomes more likely to occur with increasing length of fasting, and in people prone to headache. This has been documented as 'Yom Kippur Headache' and 'First of Ramadan Headache.' We performed a study to test the hypothesis that Rofecoxib, a pain medicine and anti-inflammatory, with a prolonged duration of action would prevent or attenuate headache when taken just prior to the complete (no food or drink) 25 hour fast of Yom Kippur.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeadache
CountriesIsrael
Collaborators--
Timeline
N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2004
Study CompletionNov 2004
First PostedDec 2005
TodayJul 2026
First PostedDec 7, 2005
Enrollment StartSep 1, 2004
Study CompletionNov 1, 2004
TodayJul 2, 2026
Posted 20.6 years ago
Interventions
Rofecoxibdrug